LinkedIn
icn_podcast Podcasts
View All Upcoming Courses
Specialty
Course Type
Search
Login
Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neuro-Ophthalmology Oculoplastics Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login
Menu

Diabetic Eye Disease Pipeline Therapies Part 3: Brolucizumab & PDS

By: Christina Y. Weng, MD, MBA (Chair); Sophie J. Bakri, MD

Begin Course

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 0.5

This discussion with Program Chair Christina Y. Weng, MD, MBA, and Sophie J. Bakri, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial. 

Drs. Weng and Bakri also converse about the latest data on pipeline therapies for diabetic macular edema, including brolucizumab & PDS.

Expiration Date: Friday, March 31, 2023
Release Date: December 8, 2021

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Describe the pros and cons of current therapy options for diabetic eye disease and wet age-related macular degeneration (AMD).
  • Articulate the challenges facing retina specialists related to the complexities of managing patients with diabetic retinopathy, diabetic macular edema, and wet AMD.
  • Assess pipeline candidates under investigation for these patient populations.

Accreditation and Designation Statement

Provided by Evolve Medical Education LLC (Evolve).

Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Evolve designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Christina Y. Weng, MD, MBA (Chair)

Associate Professor of Ophthalmology
Fellowship Program Director
Vitreoretinal Diseases & Surgery
Baylor College of Medicine
Cullen Eye Institute

Sophie J. Bakri, MD

Professor and Chair
Department of Ophthalmology
Mayo Clinic

Rochester, MN
 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Christina Y. Weng, MD, MBA,  has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Alimera Sciences, Allergan/AbbVie, DORC, Genentech, Novartis, Regeneron Pharmaceuticals, and Regenxbio.

Sophie J. Bakri, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Allergan, Alimera, Apellis, Eyepoint Pharmaceuticals, Regenexbio, Genentech, Kala Pharmaceuticals, Novartis, and Roche.

The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.

Begin Course